Zydus Lifesciences has received **final USFDA approval** for its **Ascorbic Acid Injection USP** under the Competitive Generic Therapy (CGT) pathway. 🚀 🔹 **Potential 180-day CGT exclusivity** 🔹 US market opportunity of around **$11.6 million** annually 🔹 Product to be manufactured at Zydus' injectable facility in **Jarod, Gujarat** 🔹 Will be marketed through **Zydus Pharmaceuticals (USA) Inc.** 🔹 Total **448 USFDA approvals** and **513 ANDA filings** as of June 30, 2026 📈 **Our View:** The approval strengthens Zydus' US injectable portfolio. The potential 180-day exclusivity could provide an initial competitive advantage and support better product economics. ⚠️ *Disclaimer: This post is for educational and informational purposes only. Not a recommendation or investment advice.* **Follow AFS Trading Edge for market-moving corporate updates and insights.** 📊🚀

ZYDUSLIFE

#IndexStrategies#Today’sTradingSetup#WatchOutFor#EquityResearch#FundamentalViews

868 likes·61 comments